AllianceBernstein
SVA

AllianceBernstein’s Sinovac Biotech, Ltd SVA Stock Holding History

AllianceBernstein’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-49
Closed – – 3945
2014
Q1 		$0 Hold
49
– – ﹤0.01% 3794
2013
Q4 		$0 Hold
49
– – ﹤0.01% 3592
2013
Q3 		$0 Buy
+49
New +$234 ﹤0.01% 3599

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein's SVA Position: Q2 2014 in Review

AllianceBernstein sold out of Sinovac Biotech, Ltd (SVA) in Q2 2014, closing a stake of 49 shares.

AllianceBernstein first reported a position in SVA in Q3 2013 and held it in 3 quarters. The position peaked at $0 in Q1 2014. 50 funds tracked by Wall St. Rank hold SVA as of Q2 2014.

  • AllianceBernstein reported no remaining Sinovac Biotech, Ltd position as of Q2 2014 after selling out during the quarter.
  • AllianceBernstein sold 49 Sinovac Biotech, Ltd shares in Q2 2014.
  • AllianceBernstein first reported a position in Sinovac Biotech, Ltd in Q3 2013 and held it in 3 quarters.
  • AllianceBernstein's Sinovac Biotech, Ltd position peaked at $0 in Q1 2014.
  • 50 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2014.

Based on AllianceBernstein's 13F filing for Q2 2014, filed 13 Aug 2014.